Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis

BACKGROUND: Latest clinical trials have proved the better overall survival (OS) for the use of immune checkpoint inhibitors verse chemotherapy in non-small cell lung cancer (NSCLC) patients. However, we still have no clear ideas of the factors which could affect the efficacy of immune checkpoint inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Rui, Zhu, Jing, Liu, Ying, Xin, Ying, Wang, Ying, Niu, Kai, Wei, Huafang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969231/
https://www.ncbi.nlm.nih.gov/pubmed/33725808
http://dx.doi.org/10.1097/MD.0000000000019713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969231/
https://www.ncbi.nlm.nih.gov/pubmed/33725808
http://dx.doi.org/10.1097/MD.0000000000019713

Ejemplares similares